The first 10 prescription drugs up for Medicare price negotiations have had years of price hikes that have ratcheted up costs for US taxpayers—which totaled $50.5 billion in gross Medicare Part D coverage costs in the past year and $3.4 billion in out-of-pocket costs in 2022.
Today, the Department of Health and Human Services announced the 10 drugs selected for the first round of Medicare price negotiations, established under the Inflation Reduction Act. All but one of the announced drugs were among the top 25 costliest Medicare Part D prescriptions in 2021. An analysis by the AARP
→ Continue reading at Ars Technica